30/07/2026 CREATE Medicines announced that it had received approval to initiate a Phase 1/2 trial of CRT-402 for autoimmune diseases Pfizer announced topline Phase 3 results for LITFULO in Patients with Nonsegmental Vitiligo CREATE Medicines announced that it had received approval to initiate a Phase 1/2 trial of CRT-402 for autoimmune diseases (Ref) CREATE Medicines announced that it had received Human Research Ethics Committee (HREC) approval in Australia to begin its Phase

29/07/2026 AbbVie announced European Commission approval of RINVOQ® for non-segmental vitiligo AbbVie announced European Commission approval of RINVOQ® for severe alopecia areata Johnson & Johnson announced a strategic collaboration with Sail Biomedicines to develop in vivo CAR-T therapies for autoimmune diseases AbbVie announced European Commission approval of RINVOQ® for non-segmental vitiligo (Ref) AbbVie announced that the European Commission (EC) approved RINVOQ® (upadac

29/06/2026 Abbvie received positive CHMP opinion for upadacitinib for the treatment of adults and adolescents with Non-segmental Vitiligo Abbvie received positive CHMP opinion for upadacitinib for the treatment of adults and adolescents with severe alopecia areata Zura Bio exceeded Phase 2 enrollment target for HS and SSc and expanded tibulizumab program Dianthus Therapeutics announced the initiation of a Phase 3 trial of claseprubart in gMG Abivax announced ABETACT maintenan